NCT06128564View on ClinicalTrials.gov

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

May 30, 2033

Study Completion Date

May 30, 2033

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

delandistrogene moxeparvovec

Single IV infusion of delandistrogene moxeparvovec

Trial Locations (7)

3500

RECRUITING

Chr de La Citadelle, Liège

45147

RECRUITING

Universitätsklinikum Essen, Essen

75015

RECRUITING

Hôpital Necker-Enfants Malades, Paris

00168

RECRUITING

PU A. Gemelli, Università Cattolica del Sacro Cuore, Rome

08950

RECRUITING

Hospital Sant Joan De Deu, Esplugues de Llobregas

WC1N 3JH

RECRUITING

Great Ormond Street Hospital for Children, London

OX3 9DU

RECRUITING

John Radcliffe Hospital, Oxford

All Listed Sponsors
collaborator

Sarepta Therapeutics, Inc.

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY